Abstract
Rationale: Development of diagnostic tools with improved predictive value for tuberculosis (TB) is a global research priority. Objectives: We evaluated whether implementing higher diagnostic thresholds than currently recommended for QuantiFERON Gold-in-Tube (QFT-GIT), T-SPOT.TB, and the tuberculin skin test (TST) might improve prediction of incident TB. Methods: Follow-up of a UK cohort of 9,610 adult TB contacts and recent migrants was extended by relinkage to national TB surveillance records (median follow-up 4.7 yr). Incidence rates and rate ratios, sensitivities, specificities, and predictive values for incident TB were calculated according to ordinal strata for quantitative results of QFT-GIT, T-SPOT.TB, and TST (with adjustment for prior bacillus Calmette-Guérin [BCG] vaccination). Measurements and Main Results: For all tests, incidence rates and rate ratios increased with the magnitude of the test result (P < 0.0001). Over 3 years’ follow-up, there was a modest increase in positive predictive value with the higher thresholds (3.0% for QFT-GIT ≥0.35 IU/ml vs. 3.6% for ≥4.00 IU/ml; 3.4% for T-SPOT.TB ≥5 spots vs. 5.0% for ≥50 spots; and 3.1% for BCG-adjusted TST ≥5 mm vs. 4.3% for ≥15 mm). As thresholds increased, sensitivity to detect incident TB waned for all tests (61.0% for QFT-GIT ≥0.35 IU/ml vs. 23.2% for ≥4.00 IU/ml; 65.4% for T-SPOT.TB ≥5 spots vs. 27.2% for ≥50 spots; 69.7% for BCG-adjusted TST ≥5 mm vs. 28.1% for ≥15 mm). Conclusions: Implementation of higher thresholds for QFT-GIT, T-SPOT.TB, and TST modestly increases positive predictive value for incident TB, but markedly reduces sensitivity. Novel biomarkers or validated multivariable risk algorithms are required to improve prediction of incident TB.
Original language | English |
---|---|
Pages (from-to) | 984-991 |
Number of pages | 8 |
Journal | American Journal of Respiratory and Critical Care Medicine |
Volume | 201 |
Issue number | 8 |
DOIs | |
Publication status | Published - 15 Apr 2020 |
Bibliographical note
Funding Information:Supported by National Institute for Health Research Health Technology Assessment Program 08-68-01. In addition, R.K.G. was funded by the National Institute for Health Research (NIHR) (DRF-2018-11-ST2-004). I.A. was funded by NIHR (SRF-2011-04-001; NF-SI-0616-10037), Medical Research Council, UK Department of Health, and the Wellcome Trust. A.L. was funded by a Wellcome Trust Senior Research Fellowship in Clinical Science, an NIHR Senior Investigator Award, and the NIHR Health Protection Research Unit in Respiratory Infection. F.D. was supported by the NIHR Imperial Biomedical Research Centre. M.N. is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to University College London and University College London Hospitals.
Keywords
- Epidemiology
- Latent tuberculosis
- QuantiFERON
- Screening
- T-SPOT.TB